| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 35 | 2025 | 101 | 8.030 |
Why?
|
| Coronary Artery Disease | 15 | 2024 | 371 | 4.080 |
Why?
|
| Cardiovascular Diseases | 25 | 2024 | 752 | 3.890 |
Why?
|
| Vascular Calcification | 12 | 2024 | 47 | 3.790 |
Why?
|
| Walking | 22 | 2025 | 104 | 2.880 |
Why?
|
| Exercise Therapy | 15 | 2023 | 94 | 2.830 |
Why?
|
| Coronary Vessels | 9 | 2022 | 175 | 2.620 |
Why?
|
| Walk Test | 14 | 2025 | 31 | 2.350 |
Why?
|
| Exercise | 8 | 2024 | 353 | 2.250 |
Why?
|
| Myocardial Infarction | 16 | 2025 | 375 | 2.240 |
Why?
|
| Exercise Test | 8 | 2022 | 151 | 1.980 |
Why?
|
| Atherosclerosis | 9 | 2024 | 254 | 1.960 |
Why?
|
| Blood Pressure | 14 | 2024 | 887 | 1.680 |
Why?
|
| Ankle Brachial Index | 13 | 2024 | 27 | 1.650 |
Why?
|
| Coronary Disease | 5 | 2024 | 221 | 1.620 |
Why?
|
| Lower Extremity | 11 | 2022 | 99 | 1.570 |
Why?
|
| Calcium | 8 | 2022 | 1173 | 1.510 |
Why?
|
| Exercise Tolerance | 7 | 2025 | 63 | 1.450 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2025 | 177 | 1.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2024 | 393 | 1.220 |
Why?
|
| Aspirin | 12 | 2025 | 164 | 1.220 |
Why?
|
| Intermittent Claudication | 6 | 2025 | 19 | 1.220 |
Why?
|
| Muscle, Skeletal | 8 | 2025 | 473 | 1.140 |
Why?
|
| Humans | 117 | 2025 | 93132 | 1.050 |
Why?
|
| Heart Failure | 8 | 2025 | 1376 | 1.040 |
Why?
|
| Aged | 62 | 2025 | 20395 | 1.030 |
Why?
|
| Stroke | 13 | 2024 | 1073 | 1.010 |
Why?
|
| Evidence-Based Medicine | 6 | 2018 | 451 | 0.980 |
Why?
|
| Antihypertensive Agents | 6 | 2023 | 256 | 0.940 |
Why?
|
| Calcinosis | 2 | 2022 | 219 | 0.930 |
Why?
|
| Hypertension | 9 | 2024 | 748 | 0.910 |
Why?
|
| Female | 71 | 2025 | 48542 | 0.800 |
Why?
|
| Menstruation Disturbances | 1 | 2023 | 22 | 0.800 |
Why?
|
| Practice Guidelines as Topic | 7 | 2024 | 1054 | 0.800 |
Why?
|
| Anemia | 4 | 2025 | 129 | 0.790 |
Why?
|
| Male | 68 | 2025 | 44355 | 0.770 |
Why?
|
| Middle Aged | 54 | 2025 | 27535 | 0.760 |
Why?
|
| Cholesterol | 4 | 2018 | 364 | 0.760 |
Why?
|
| Cardiology | 7 | 2018 | 120 | 0.760 |
Why?
|
| Menstrual Cycle | 1 | 2023 | 65 | 0.760 |
Why?
|
| Kidney Diseases | 2 | 2019 | 309 | 0.760 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 57 | 0.750 |
Why?
|
| Secondary Prevention | 7 | 2024 | 173 | 0.750 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 279 | 0.750 |
Why?
|
| Risk Factors | 23 | 2024 | 5900 | 0.730 |
Why?
|
| Leg | 5 | 2023 | 139 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2023 | 916 | 0.670 |
Why?
|
| Femoral Artery | 3 | 2017 | 90 | 0.660 |
Why?
|
| Diabetic Angiopathies | 2 | 2012 | 37 | 0.650 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2017 | 58 | 0.650 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2019 | 258 | 0.620 |
Why?
|
| Cardiotoxicity | 1 | 2019 | 13 | 0.580 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 238 | 0.580 |
Why?
|
| Masked Hypertension | 1 | 2018 | 1 | 0.580 |
Why?
|
| Panic Disorder | 1 | 2018 | 21 | 0.570 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 36 | 0.570 |
Why?
|
| Obesity | 3 | 2023 | 1014 | 0.560 |
Why?
|
| Weight Gain | 1 | 2019 | 127 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 2562 | 0.550 |
Why?
|
| Predictive Value of Tests | 11 | 2024 | 1703 | 0.540 |
Why?
|
| Weight Loss | 1 | 2019 | 234 | 0.530 |
Why?
|
| Legislation, Food | 1 | 2017 | 1 | 0.520 |
Why?
|
| Trans Fatty Acids | 1 | 2017 | 1 | 0.520 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 762 | 0.510 |
Why?
|
| Mitochondria, Muscle | 3 | 2024 | 24 | 0.510 |
Why?
|
| Diet | 2 | 2017 | 461 | 0.490 |
Why?
|
| Risk Assessment | 14 | 2025 | 2434 | 0.490 |
Why?
|
| Smoking | 3 | 2017 | 647 | 0.480 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 28 | 0.480 |
Why?
|
| Erythrocyte Transfusion | 3 | 2025 | 74 | 0.470 |
Why?
|
| Arteries | 1 | 2017 | 170 | 0.470 |
Why?
|
| Mass Screening | 2 | 2012 | 706 | 0.460 |
Why?
|
| Home Care Services | 1 | 2016 | 69 | 0.460 |
Why?
|
| Coronary Angiography | 4 | 2024 | 232 | 0.450 |
Why?
|
| Hospitalization | 5 | 2024 | 924 | 0.450 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 140 | 0.440 |
Why?
|
| Breast | 1 | 2017 | 302 | 0.440 |
Why?
|
| Time Factors | 12 | 2025 | 5380 | 0.430 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 256 | 0.430 |
Why?
|
| Aged, 80 and over | 15 | 2024 | 7039 | 0.430 |
Why?
|
| Ischemia | 4 | 2021 | 252 | 0.420 |
Why?
|
| Body Mass Index | 2 | 2017 | 806 | 0.420 |
Why?
|
| Pharmacogenetics | 4 | 2019 | 456 | 0.410 |
Why?
|
| C-Reactive Protein | 5 | 2018 | 204 | 0.410 |
Why?
|
| Mobility Limitation | 4 | 2023 | 20 | 0.410 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2022 | 58 | 0.400 |
Why?
|
| American Heart Association | 4 | 2018 | 106 | 0.400 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2013 | 19 | 0.390 |
Why?
|
| Mammography | 1 | 2017 | 494 | 0.390 |
Why?
|
| Particulate Matter | 2 | 2024 | 123 | 0.380 |
Why?
|
| Blood Glucose | 1 | 2017 | 866 | 0.380 |
Why?
|
| Blood Transfusion | 2 | 2024 | 171 | 0.380 |
Why?
|
| Prevalence | 5 | 2022 | 1318 | 0.360 |
Why?
|
| Biomarkers | 10 | 2024 | 1905 | 0.360 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 290 | 0.350 |
Why?
|
| Medicare | 3 | 2023 | 451 | 0.350 |
Why?
|
| Treatment Outcome | 13 | 2025 | 9070 | 0.340 |
Why?
|
| United States | 18 | 2024 | 7581 | 0.340 |
Why?
|
| Quality of Life | 5 | 2025 | 1776 | 0.330 |
Why?
|
| Albuminuria | 1 | 2010 | 51 | 0.320 |
Why?
|
| Anticholesteremic Agents | 3 | 2018 | 154 | 0.320 |
Why?
|
| Troponin T | 2 | 2021 | 41 | 0.310 |
Why?
|
| Tunica Intima | 2 | 2010 | 61 | 0.310 |
Why?
|
| Hemorrhage | 7 | 2024 | 289 | 0.300 |
Why?
|
| Dyslipidemias | 2 | 2024 | 107 | 0.300 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 100 | 0.300 |
Why?
|
| Ankle | 1 | 2009 | 21 | 0.290 |
Why?
|
| Brachial Artery | 1 | 2009 | 37 | 0.290 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 56 | 0.290 |
Why?
|
| Blood Pressure Determination | 1 | 2009 | 69 | 0.290 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 76 | 0.290 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 753 | 0.280 |
Why?
|
| Incidence | 4 | 2022 | 1697 | 0.280 |
Why?
|
| Stroke Volume | 4 | 2025 | 434 | 0.280 |
Why?
|
| Erectile Dysfunction | 1 | 2009 | 77 | 0.280 |
Why?
|
| Lipids | 4 | 2023 | 277 | 0.280 |
Why?
|
| DNA, Mitochondrial | 2 | 2020 | 200 | 0.280 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2301 | 0.280 |
Why?
|
| Adult | 15 | 2024 | 27849 | 0.270 |
Why?
|
| Research Design | 4 | 2023 | 620 | 0.270 |
Why?
|
| Niacin | 1 | 2008 | 37 | 0.270 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 113 | 0.270 |
Why?
|
| Follow-Up Studies | 9 | 2025 | 3814 | 0.260 |
Why?
|
| Cohort Studies | 8 | 2024 | 3044 | 0.260 |
Why?
|
| Hypolipidemic Agents | 1 | 2008 | 96 | 0.260 |
Why?
|
| Overweight | 2 | 2019 | 120 | 0.250 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 300 | 0.250 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 150 | 0.250 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 378 | 0.240 |
Why?
|
| Double-Blind Method | 7 | 2025 | 1727 | 0.240 |
Why?
|
| Air Pollution | 2 | 2024 | 107 | 0.240 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1098 | 0.230 |
Why?
|
| Recovery of Function | 3 | 2025 | 340 | 0.230 |
Why?
|
| Heart Rate | 2 | 2020 | 505 | 0.230 |
Why?
|
| Sleep Apnea, Central | 1 | 2025 | 16 | 0.230 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2025 | 67 | 0.230 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 30 | 0.230 |
Why?
|
| Office Visits | 1 | 2025 | 47 | 0.220 |
Why?
|
| Appointments and Schedules | 1 | 2025 | 58 | 0.220 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2023 | 19 | 0.220 |
Why?
|
| Environmental Exposure | 2 | 2024 | 355 | 0.220 |
Why?
|
| Cell Respiration | 1 | 2024 | 20 | 0.220 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2017 | 267 | 0.210 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2025 | 86 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 1910 | 0.210 |
Why?
|
| Precision Medicine | 5 | 2025 | 457 | 0.210 |
Why?
|
| Carotid Arteries | 3 | 2010 | 130 | 0.200 |
Why?
|
| Income | 1 | 2024 | 86 | 0.200 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 108 | 0.200 |
Why?
|
| Chicago | 7 | 2023 | 1452 | 0.200 |
Why?
|
| Oxygen Consumption | 1 | 2024 | 233 | 0.200 |
Why?
|
| Weight Reduction Programs | 1 | 2023 | 12 | 0.200 |
Why?
|
| Disease Progression | 5 | 2020 | 1529 | 0.190 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 246 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 107 | 0.190 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1925 | 0.190 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 44 | 0.180 |
Why?
|
| Genetic Therapy | 1 | 2025 | 365 | 0.180 |
Why?
|
| Insurance Coverage | 1 | 2023 | 141 | 0.180 |
Why?
|
| Life Style | 2 | 2014 | 183 | 0.180 |
Why?
|
| Primary Prevention | 1 | 2022 | 87 | 0.170 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 1160 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2024 | 941 | 0.170 |
Why?
|
| Dependent Ambulation | 2 | 2017 | 3 | 0.170 |
Why?
|
| Dementia | 1 | 2023 | 213 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2021 | 4546 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1229 | 0.160 |
Why?
|
| Ribose | 1 | 2020 | 20 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 85 | 0.160 |
Why?
|
| Rest | 1 | 2020 | 50 | 0.160 |
Why?
|
| Glucose | 1 | 2023 | 686 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2020 | 42 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2022 | 212 | 0.160 |
Why?
|
| Chocolate | 1 | 2020 | 1 | 0.160 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 54 | 0.160 |
Why?
|
| Echocardiography | 3 | 2010 | 748 | 0.160 |
Why?
|
| Recommended Dietary Allowances | 1 | 2019 | 3 | 0.160 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 334 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1719 | 0.160 |
Why?
|
| Cholesterol, Dietary | 1 | 2019 | 26 | 0.160 |
Why?
|
| Nutrition Policy | 1 | 2019 | 12 | 0.160 |
Why?
|
| Catechin | 1 | 2020 | 22 | 0.150 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 150 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 627 | 0.150 |
Why?
|
| Diet, Western | 1 | 2019 | 45 | 0.150 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2017 | 39 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2024 | 218 | 0.150 |
Why?
|
| Muscle Strength | 1 | 2019 | 38 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 122 | 0.150 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 116 | 0.150 |
Why?
|
| Anthracyclines | 1 | 2019 | 31 | 0.150 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2705 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2019 | 10128 | 0.140 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 1909 | 0.140 |
Why?
|
| Disease Management | 2 | 2019 | 357 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 111 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2019 | 38 | 0.140 |
Why?
|
| Organ Size | 1 | 2019 | 360 | 0.140 |
Why?
|
| Insulin | 1 | 2023 | 1184 | 0.140 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 90 | 0.140 |
Why?
|
| Home Nursing | 1 | 2018 | 16 | 0.140 |
Why?
|
| Necrosis | 2 | 2017 | 203 | 0.130 |
Why?
|
| Cholesterol, HDL | 2 | 2009 | 173 | 0.130 |
Why?
|
| Electronic Health Records | 2 | 2021 | 373 | 0.130 |
Why?
|
| Risk | 2 | 2021 | 651 | 0.130 |
Why?
|
| Comorbidity | 3 | 2018 | 1003 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2025 | 888 | 0.130 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 36 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 218 | 0.130 |
Why?
|
| Physical Endurance | 1 | 2017 | 11 | 0.130 |
Why?
|
| Young Adult | 3 | 2023 | 6922 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 160 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 155 | 0.130 |
Why?
|
| Collateral Circulation | 1 | 2017 | 36 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2017 | 90 | 0.130 |
Why?
|
| New York | 1 | 2017 | 78 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 192 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2021 | 1004 | 0.130 |
Why?
|
| Biopsy | 4 | 2024 | 1172 | 0.120 |
Why?
|
| Fasting | 1 | 2017 | 164 | 0.120 |
Why?
|
| Educational Status | 1 | 2017 | 195 | 0.120 |
Why?
|
| Prognosis | 5 | 2022 | 3890 | 0.120 |
Why?
|
| Antioxidants | 1 | 2017 | 231 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 561 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 573 | 0.120 |
Why?
|
| Family Health | 1 | 2016 | 154 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1849 | 0.110 |
Why?
|
| Physician's Role | 1 | 2017 | 175 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 626 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1908 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 2787 | 0.110 |
Why?
|
| Health Status | 1 | 2017 | 373 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 162 | 0.110 |
Why?
|
| Oscillometry | 1 | 2014 | 25 | 0.110 |
Why?
|
| Kidney | 1 | 2019 | 1093 | 0.100 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 72 | 0.100 |
Why?
|
| Patient Selection | 1 | 2018 | 688 | 0.100 |
Why?
|
| Random Allocation | 1 | 2014 | 308 | 0.100 |
Why?
|
| Genome, Human | 1 | 2019 | 823 | 0.100 |
Why?
|
| Logistic Models | 2 | 2025 | 1240 | 0.100 |
Why?
|
| Pyrroles | 1 | 2014 | 165 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2017 | 310 | 0.100 |
Why?
|
| Celiac Disease | 1 | 2016 | 219 | 0.100 |
Why?
|
| Electrocardiography | 1 | 2015 | 496 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 21 | 0.090 |
Why?
|
| Child | 1 | 2023 | 7273 | 0.090 |
Why?
|
| HIV Infections | 1 | 2021 | 952 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 618 | 0.090 |
Why?
|
| Professional Practice | 1 | 2011 | 43 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 42 | 0.090 |
Why?
|
| Uncertainty | 1 | 2012 | 78 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 135 | 0.080 |
Why?
|
| Postmenopause | 2 | 2022 | 106 | 0.080 |
Why?
|
| Adolescent | 1 | 2023 | 9550 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 170 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 381 | 0.080 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 221 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 338 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2010 | 49 | 0.070 |
Why?
|
| Image Enhancement | 2 | 2010 | 498 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2022 | 468 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 282 | 0.070 |
Why?
|
| Forecasting | 1 | 2010 | 288 | 0.070 |
Why?
|
| Sulfonylurea Compounds | 1 | 2009 | 71 | 0.070 |
Why?
|
| Fluorocarbons | 1 | 2009 | 49 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 216 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1102 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2020 | 183 | 0.070 |
Why?
|
| Embolism | 1 | 2008 | 32 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 448 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2020 | 236 | 0.070 |
Why?
|
| Triglycerides | 1 | 2008 | 231 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 709 | 0.060 |
Why?
|
| Attitude to Health | 2 | 2017 | 214 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2020 | 150 | 0.060 |
Why?
|
| Artifacts | 1 | 2009 | 241 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2008 | 184 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 2007 | 53 | 0.060 |
Why?
|
| Consensus | 2 | 2018 | 366 | 0.060 |
Why?
|
| Critical Illness | 2 | 2020 | 342 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 188 | 0.060 |
Why?
|
| Polysomnography | 1 | 2025 | 152 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2025 | 63 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3450 | 0.050 |
Why?
|
| Systole | 1 | 2024 | 81 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2007 | 199 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 58 | 0.050 |
Why?
|
| Diastole | 1 | 2024 | 99 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2025 | 120 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2008 | 407 | 0.050 |
Why?
|
| Algorithms | 2 | 2010 | 1948 | 0.050 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 7 | 0.050 |
Why?
|
| Ticlopidine | 1 | 2023 | 24 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 10 | 0.050 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2006 | 332 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2023 | 66 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2007 | 450 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 181 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 188 | 0.050 |
Why?
|
| Air Pollutants | 1 | 2024 | 108 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 175 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 195 | 0.050 |
Why?
|
| Hypoxia | 1 | 2007 | 672 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 239 | 0.040 |
Why?
|
| Temperature | 1 | 2023 | 421 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 346 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 239 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 73 | 0.040 |
Why?
|
| Internet | 1 | 2023 | 345 | 0.040 |
Why?
|
| Medicaid | 1 | 2023 | 245 | 0.040 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2020 | 7 | 0.040 |
Why?
|
| ROC Curve | 2 | 2016 | 774 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 56 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1188 | 0.040 |
Why?
|
| Adenosine Diphosphate | 1 | 2020 | 58 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 119 | 0.040 |
Why?
|
| Sick Role | 1 | 2000 | 13 | 0.040 |
Why?
|
| Research Personnel | 1 | 2021 | 78 | 0.040 |
Why?
|
| Beverages | 1 | 2020 | 16 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2020 | 46 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2000 | 164 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 255 | 0.040 |
Why?
|
| Communication | 2 | 2019 | 433 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 369 | 0.040 |
Why?
|
| Urban Population | 1 | 2000 | 234 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 131 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 18 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 174 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 36 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 163 | 0.030 |
Why?
|
| Research | 1 | 2019 | 250 | 0.030 |
Why?
|
| Research Report | 1 | 2017 | 43 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 873 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 234 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2016 | 28 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 92 | 0.030 |
Why?
|
| Tomography, Spiral Computed | 1 | 2016 | 75 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 125 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 336 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2016 | 99 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 557 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 228 | 0.030 |
Why?
|
| Stem Cells | 1 | 2017 | 386 | 0.030 |
Why?
|
| Telemedicine | 1 | 2018 | 223 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 913 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 874 | 0.030 |
Why?
|
| Heparin | 1 | 1995 | 177 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 432 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 1995 | 210 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 618 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 128 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 995 | 0.020 |
Why?
|
| Tunica Media | 1 | 2010 | 16 | 0.020 |
Why?
|
| Shear Strength | 1 | 2010 | 17 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2010 | 34 | 0.020 |
Why?
|
| Microbubbles | 1 | 2008 | 39 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 584 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2007 | 40 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2008 | 263 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 99 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 117 | 0.020 |
Why?
|
| Computer Systems | 1 | 2006 | 63 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2007 | 138 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2007 | 295 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 986 | 0.010 |
Why?
|
| Movement | 1 | 2006 | 307 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 753 | 0.010 |
Why?
|
| Myocardium | 1 | 2006 | 567 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1519 | 0.010 |
Why?
|
| Nursing Methodology Research | 1 | 2000 | 11 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2000 | 167 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2000 | 167 | 0.010 |
Why?
|
| Viral Plaque Assay | 1 | 1995 | 17 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 1995 | 18 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1995 | 18 | 0.010 |
Why?
|
| Vero Cells | 1 | 1995 | 98 | 0.010 |
Why?
|
| Virion | 1 | 1995 | 61 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 422 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 1463 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1995 | 661 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 2889 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 2458 | 0.010 |
Why?
|
| Animals | 1 | 1995 | 27973 | 0.000 |
Why?
|